ArticleMemorias do Instituto Oswaldo Cruz2018
Type-2 diabetes alters the basal phenotype of human macrophages and diminishes their capacity to respond, internalise, and control Mycobacterium tuberculosis.
Article in Memorias do Instituto Oswaldo Cruz, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it, 58 citations in OpenAlex.
- Immune dysregulation in tuberculosis-diabetes comorbidity: mechanistic and translational insights.Frontiers in immunology · 2026Pooled it
- Type 1 diabetes alters early macrophage-iScience · 2026Article
- Chemerin Exacerbates Pulmonary Inflammation in Type 2 Diabetes and Mycobacterium Tuberculosis Infection Comorbidity.Inflammation · 2025Article
- Human alveolar macrophage function is impaired in tuberculosis contacts with diabetes.EBioMedicine · 2025Article
- A Case Report of Wound Infection Caused byInfection and drug resistance · 2025Article
- Impact of diabetes mellitus on tuberculosis prevention, diagnosis, and treatment from an immunologic perspective.Exploration (Beijing, China) · 2024Review
- Assessing the effects of diabetes mellitus on the monocyte-to-lymphocyte ratio and the QuantiFERON-TB gold plus assays for tuberculosis treatment monitoring: a prospective cohort study.Frontiers in immunology · 2024Article
- ImpairedFrontiers in immunology · 2024Article
- Immune-endocrine network in diabetes-tuberculosis nexus: does latent tuberculosis infection confer protection against meta-inflammation and insulin resistance?Frontiers in endocrinology · 2024Review
- Diabetes Mellitus Type 2 as a Risk Factor and Outcome Modifier for Cryptococcosis in HIV Negative, Non-transplant Patients, a Propensity Score Match Analysis.Current microbiology · 2023Article
- Host-directed therapy against mycobacterium tuberculosis infections with diabetes mellitus.Frontiers in immunology · 2023Review
- Immunologic, metabolic and genetic impact of diabetes on tuberculosis susceptibility.Frontiers in immunology · 2023Review
- Risk factors for multidrug resistance in tuberculosis patients with diabetes mellitus.BMC infectious diseases · 2022Article
- Impact of Diabetes Mellitus on the Immunity of Tuberculosis Patients: A Retrospective, Cross-Sectional Study.Risk management and healthcare policy · 2022Article
- Screening of latent tuberculosis infection among patients with diabetes mellitus from a high-burden area in Brazil.Frontiers in clinical diabetes and healthcare · 2022Article
- Cellular Immunity of Patients with Tuberculosis Combined with Diabetes.Journal of immunology research · 2022Review
- Diabetes-Associated Susceptibility to Tuberculosis: Contribution of Hyperglycemia vs. Dyslipidemia.Microorganisms · 2021Review
- Molecular mechanism of interaction ofBiochemistry and biophysics reports · 2021Article
- Hyperglycemia and dyslipidemia: Reduced HLA-DR expression in monocyte subpopulations from diabetes patients.Human immunology · 2021Observational
- Pharmacological Poly (ADP-Ribose) Polymerase Inhibitors DecreaseFrontiers in immunology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundType 2 diabetes (T2D) is a risk factor for the development of tuberculosis (TB), although the associated mechanisms are not known.
objectivesTo study the association between T2D and the basal phenotype of macrophages, and their immune response to Mycobacterium tuberculosis (Mtb) infection.
methodsWe evaluated the influence of T2D on the response of monocyte-derived macrophages (MDM) to Mtb in patients with T2D (n = 10) compared to healthy subjects (n = 9), before and after infection with Mtb clinical isolates bearing different degrees of virulence. The levels of cell surface markers for activation secreted cytokines and chemokines, bacterial association, and intracellular bacterial growth were evaluated.
findingsThe expression levels of HLA-DR, CD80, and CD86 were low while those of of PD-L1 were high in uninfected MDMs derived from patients with diabetes; as a result of Mtb infection, changes were only observed in the expression levels of PD-L1. The levels of cytokines (e.g., IL-6, IL-1β, IL-10, and IL-12) and chemokines (e.g., MCP-1, MIG, and RANTES) are perturbed in MDMs derived from patients with diabetes, both before infection and in response to Mtb infection. In response to the more virulent Mtb strains, the levels of association and bacterial clearance were diminished in MDMs derived from patients with diabetes.
conclusionsT2D affects the basal activation state of the macrophages and its capacity to respond and control Mtb infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.